Symbols

TYME(Delisted)

Tyme Technologies·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TYME

Tyme Technologies, Inc.

effective and low-toxic anti-cancer drugs

Industry

Established Date

11/22/2011

Listing Date

07/31/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

03-31

Website

www.tymeinc.com

Security Type

Common stock

Office address

1 Pluckemin Way–Suite 103, Bedminster, NJ, 07921

Business

Introduction

Tyme Technologies, Inc., was first established on November 22, 2011, formerly known as "Global Group Enterprises Corp", and was later reorganized on September 18, 2014. The company is a clinical-stage biotechnology company focused on the development of effective and low-toxic anticancer drugs, unlike targeted therapies that try to modulate specific mutations in cancer, their treatments are designed to exploit the innate metabolic weaknesses of cancer cells to destroy their defenses. The company's current main product is SM-88, which is in the preparation stage for clinical trials.

Company Financials

EPS

TYME has released its 2022 Q4 earnings. EPS was reported at -0.03, versus the expected 0, missing expectations. The chart below visualizes how TYME has performed over recent quarters, highlighting trends in earnings surprises.